A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer

John J. Kavanagh; Larry J. Copeland; David M. Gershenson; Patton B. Saul; Creighton L. Edwards

doi:10.1016/0090-8258(86)90004-1

A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer

John J. Kavanagh, Larry J. Copeland, David M. Gershenson, Patton B. Saul, Creighton L. Edwards

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.

Original language	English (US)
Pages (from-to)	23-26
Number of pages	4
Journal	Gynecologic oncology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/0090-8258(86)90004-1
State	Published - May 1986

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/0090-8258(86)90004-1

Cite this

@article{b7949065ed594d6b978a675d63689937,

title = "A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer",

abstract = "Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.",

author = "Kavanagh, {John J.} and Copeland, {Larry J.} and Gershenson, {David M.} and Saul, {Patton B.} and Edwards, {Creighton L.}",

year = "1986",

month = may,

doi = "10.1016/0090-8258(86)90004-1",

language = "English (US)",

volume = "24",

pages = "23--26",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer

AU - Kavanagh, John J.

AU - Copeland, Larry J.

AU - Gershenson, David M.

AU - Saul, Patton B.

AU - Edwards, Creighton L.

PY - 1986/5

Y1 - 1986/5

N2 - Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.

AB - Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022636218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022636218&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(86)90004-1

DO - 10.1016/0090-8258(86)90004-1

M3 - Article

C2 - 3457752

AN - SCOPUS:0022636218

SN - 0090-8258

VL - 24

SP - 23

EP - 26

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -

A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this